Study comparing different doses and schedules of GSK Bio's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule., Trial ID 208141%2F026

Study comparing different doses and schedules of GSK Bio's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule., Trial ID 208141%2F026 | GSK